|
1
|
Dhanasekaran R, Limaye A and Cabrera R:
Hepatocellular carcinoma: Current trends in worldwide epidemiology,
risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37.
2012.PubMed/NCBI
|
|
2
|
Raimondi S, Bruno S, Mondelli MU and
Maisonneuve P: Hepatitis C virus genotype 1b as a risk factor for
hepatocellular carcinoma development: A meta-analysis. J Hepatol.
50:1142–1154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pollicino T, Squadrito G, Cerenzia G,
Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A,
Tiribelli C, et al: Hepatitis B virus maintains its pro-oncogenic
properties in the case of occult HBV infection. Gastroenterology.
126:102–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, risk factors, and screening. Semin Liver Dis.
25:143–154. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parkin DM: The global health burden of
infection-associated cancers in the year 2002. Int J Cancer.
118:3030–3044. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song P, Feng X, Zhang K, Song T, Ma K,
Kokudo N, Dong J, Yao L and Tang W: Screening for and surveillance
of high-risk patients with HBV-related chronic liver disease:
Promoting the early detection of hepatocellular carcinoma in China.
Biosci Trends. 7:1–6. 2013.PubMed/NCBI
|
|
7
|
Kiyosawa K, Umemura T, Ichijo T, Matsumoto
A, Yoshizawa K, Gad A and Tanaka E: Hepatocellular carcinoma.
Recent trends in Japan. Gastroenterology. 127 5 Suppl 1:S17–S26.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di Bisceglie AM, Lyra AC, Schwartz M,
Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel
DH, et al: Hepatitis C-related hepatocellular carcinoma in the
United States: Influence of ethnic status. Am J Gastroenterol.
98:2060–2063. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Donato F, Tagger A, Chiesa R, Ribero ML,
Tomasoni V, Fasola M, Gelatti U, Portera G, Boffetta P and Nardi G:
Hepatitis B and C virus infection, alcohol drinking, and
hepatocellular carcinoma: A case-control study in Italy. Brescia
HCC study. Hepatology. 26:579–584. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fattovich G, Giustina G, Degos F,
Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D,
Brouwer JT, et al: Morbidity and mortality in compensated cirrhosis
type C: A retrospective follow-up study of 384 patients.
Gastroenterology. 112:463–472. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kudo M, Han KH, Kokudo N, Cheng AL, Choi
BI, Furuse J, Izumi N, Park JW, Poon RT and Sakamoto M: Liver
cancer working group report. Jpn J Clin Oncol. 1 Suppl 40:i19–i27.
2010. View Article : Google Scholar
|
|
12
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
European Association for the Study of the
Liver, . European Organisation for Research and Treatment of
Cancer: EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Omata M, Lesmana LA, Tateishi R, Chen PJ,
Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, et al: Asian
pacific association for the study of the liver consensus
recommendations on hepatocellular carcinoma. Hepatol Int.
4:439–474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Makuuchi M, Kokudo N, Arii S, Futagawa S,
Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, et
al: Development of evidence-based clinical guidelines for the
diagnosis and treatment of hepatocellular carcinoma in Japan.
Hepatol Res. 38:37–51. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song PP, Gao JJ, Kokudo N, Dong JH and
Tang W: ‘Knowledge into action’ exploration of an appropriate
approach for constructing evidence-based clinical practice
guidelines for hepatocellular carcinoma. Biosci Trends. 6:147–152.
2012.PubMed/NCBI
|
|
18
|
Song P, Gao J, Inagaki Y, Kokudo N,
Hasegawa K, Sugawara Y and Tang W: Biomarkers: Evaluation of
screening for and early diagnosis of hepatocellular carcinoma in
Japan and China. Liver Cancer. 2:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song P, Tobe RG, Inagaki Y, Kokudo N,
Hasegawa K, Sugawara Y and Tang W: The management of
hepatocel-lular carcinoma around the world: A comparison of
guidelines from 2001 to 2011. Liver Int. 32:1053–1063. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farinati F, Marino D, De Giorgio M, Baldan
A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA,
Benvegnù L, et al: Diagnostic and prognostic role of
alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am
J Gastroenterol. 101:524–532. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui Z, Yu X, Guo L, Wei Y, Zheng S, Li W,
Chen P, Zhu J and Peng J: Combined analysis of serum
alpha-fetoprotein and MAGE-A3-specific cytotoxic T lymphocytes in
peripheral blood for diagnosis of hepatocellular carcinoma. Dis
Markers. 35:915–923. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suri A: Cancer testis antigens-their
importance in immunotherapy and in the early detection of cancer.
Expert Opin Biol Ther. 6:379–389. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grizzi F, Mirandola L, Qehajaj D, Cobos E,
Figueroa JA and Chiriva-Internati M: Cancer-testis antigens and
immunotherapy in the light of cancer complexity. Int Rev Immunol.
34:143–153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song MH, Choi KU, Shin DH, Lee CH and Lee
SY: Identification of the cancer/testis antigens AKAP3 and CTp11 by
SEREX in hepatocellular carcinoma. Oncol Rep. 28:1792–1798. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peng JR, Chen HS, Mou DC, Cao J, Cong X,
Qin LL, Wei L, Leng XS, Wang Y and Chen WF: Expression of
cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and
its correlation with clinical parameters. Cancer Lett. 219:223–232.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W,
Dong XY, Peng JR, Zhao HT, Rui JA, Leng XS, et al: Large scale
identification of human hepatocellular carcinoma-associated
antigens by autoantibodies. J Immunol. 169:1102–1109. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang XA, Dong XY, Qiao H, Wang YD, Peng
JR, Li Y, Pang XW, Tian C and Chen WF: Immunohistochemical analysis
of the expression of FATE/BJ-HCC-2 antigen in normal and malignant
tissues. Lab Invest. 85:205–213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garg M, Chaurasiya D, Rana R, Jagadish N,
Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, et al:
Sperm-associated antigen 9, a novel cancer testis antigen, is a
potential target for immunotherapy in epithelial ovarian cancer.
Clin Cancer Res. 13:1421–1428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jagadish N, Rana R, Mishra D, Kumar M and
Suri A: Sperm associated antigen 9 (SPAG9): A new member of c-Jun
NH2-terminal kinase (JNK) interacting protein exclusively expressed
in testis. Keio J Med. 54:66–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yi F, Ni W, Liu W, Pan X, Han X, Yang L,
Kong X, Ma R and Chang R: SPAG9 is overexpressed in human
astrocytoma and promotes cell proliferation and invasion. Tumour
Biol. 34:2849–2855. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Garg M, Kanojia D, Khosla A, Dudha N, Sati
S, Chaurasiya D, Jagadish N, Seth A, Kumar R, Gupta S, et al:
Sperm-associated antigen 9 is associated with tumor growth,
migration, and invasion in renal cell carcinoma. Cancer Res.
68:8240–8248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garg M, Kanojia D, Salhan S, Suri S, Gupta
A, Lohiya NK and Suri A: Sperm-associated antigen 9 is a biomarker
for early cervical carcinoma. Cancer. 115:2671–2683. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kanojia D, Garg M, Gupta S, Gupta A and
Suri A: Sperm-associated antigen 9, a novel biomarker for early
detection of breast cancer. Cancer Epidemiol Biomarkers Prev.
18:630–639. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garg M, Kanojia D, Suri S, Gupta S, Gupta
A and Suri A: Sperm-associated antigen 9: A novel diagnostic marker
for thyroid cancer. J Clin Endocrinol Metab. 94:4613–4618. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kanojia D, Garg M, Gupta S, Gupta A and
Suri A: Sperm-associated antigen 9 is a novel biomarker for
colorectal cancer and is involved in tumor growth and
tumorigenicity. Am J Pathol. 178:1009–1020. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao M, Zhao J and Lu F: Alpha-fetoprotein
still is a valuable diagnostic and prognosis predicting biomarker
in hepatitis B virus infection-related hepatocellular carcinoma.
Oncotarget. 7:3702–3708. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wan HG, Xu H, Gu YM, Wang H, Xu W and Zu
MH: Comparison osteopontin vs. AFP for the diagnosis of HCC: A
meta-analysis. Clin Res Hepatol Gastroenterol. 38:706–714. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ertle JM, Heider D, Wichert M, Keller B,
Kueper R, Hilgard P, Gerken G and Schlaak JF: A combination of
α-fetoprotein and des-γ-carboxy prothrombin is superior in
detection of hepatocellular carcinoma. Digestion. 87:pp. 121–131.
2013, View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hadziyannis E, Sialevris K, Georgiou A and
Koskinas J: Analysis of serum α-fetoprotein-L3% and des-γ
carboxyprothrombin markers in cases with misleading hepatocellular
carcinoma total α-fetoprotein levels. Oncol Rep. 29:835–839. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tan EM: Autoantibodies as reporters
identifying aberrant cellular mechanisms in tumorigenesis. J Clin
Invest. 108:1411–1415. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tan EM and Zhang J: Autoantibodies to
tumor-associated antigens: Reporters from the immune system.
Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dhir RN, Dworakowski W, Thangavel C and
Shapiro BH: Sexually dimorphic regulation of hepatic isoforms of
human cytochrome p450 by growth hormone. J Pharmacol Exp Ther.
316:87–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Waxman DJ and Holloway MG: Sex differences
in the expression of hepatic drug metabolizing enzymes. Mol
Pharmacol. 76:215–228. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan
EK and Tan EM: De-novo humoral immune responses to
cancer-associated autoantigens during transition from chronic liver
disease to hepatocellular carcinoma. Clin Exp Immunol. 125:3–9.
2001. View Article : Google Scholar : PubMed/NCBI
|
